Related Experiment Video

Updated: Aug 16, 2026

Polymalic Acid-based Nano Biopolymers for Targeting of Multiple Tumor Markers: An Opportunity for Personalized Medicine?
14:20

Polymalic Acid-based Nano Biopolymers for Targeting of Multiple Tumor Markers: An Opportunity for Personalized Medicine?

Published on: June 13, 2014

Antitumor activity of HER-2 inhibitors

Sridhar K Rabindran1

  • 1Wyeth Research, 401 N. Middletown Road, Pearl River, NY 10965, USA. rabinds@wyeth.com

Cancer Letters
|July 30, 2005
PubMed

Insights

Targeting cancer-driving receptor tyrosine kinases like Epidermal Growth Factor receptor (EGFR) and HER-2 shows promise. This review covers approved and developing therapies for HER-2 overexpressing tumors.

Area of Science:

  • Oncology
  • Molecular Biology
  • Pharmacology

Background:

  • ErbB family receptor tyrosine kinases, including Epidermal Growth Factor receptor (EGFR) and HER-2, are implicated in cancer development.
  • EGFR and HER-2 signaling pathways are crucial in various malignancies.
  • The tumorigenic roles of EGFR and HER-2 are extensively researched.

Purpose of the Study:

  • To review therapeutic agents targeting Epidermal Growth Factor receptor (EGFR).
  • To discuss the potential of these agents in inhibiting tumors overexpressing HER-2.
  • To explore current and emerging therapeutics for HER-2 dependent cancers.

Main Methods:

  • Review of existing literature on EGFR and HER-2 targeted therapies.
  • Analysis of approved therapeutic antibodies and small molecule kinase inhibitors.
  • Discussion of ongoing research and development for HER-2 specific treatments.

Main Results:

  • Therapeutic antibodies and small molecule kinase inhibitors targeting EGFR are approved for colon and lung cancer.
  • These agents show potential in controlling tumors with HER-2 overexpression.
  • A range of therapeutics are available or in development for HER-2 driven cancers.

Conclusions:

  • Targeted therapies against EGFR and HER-2 represent a significant advancement in cancer treatment.
  • Inhibiting EGFR and HER-2 signaling pathways offers a viable strategy for managing specific cancers.
  • Further development of HER-2 targeted agents is crucial for improving outcomes in HER-2 dependent tumors.

More Related Videos

Determining Optimal Cytotoxic Activity of Human Her2neu Specific CD8 T cells by Comparing the Cr51 Release Assay to the xCELLigence System11:31

Determining Optimal Cytotoxic Activity of Human Her2neu Specific CD8 T cells by Comparing the Cr51 Release Assay to the xCELLigence System

Published on: August 8, 2012

Validated Immunochemical Assay for Comprehensive Determination of the Human Epidermal Growth Factor Receptor 2 Released from and Bound to Cells08:28

Validated Immunochemical Assay for Comprehensive Determination of the Human Epidermal Growth Factor Receptor 2 Released from and Bound to Cells

Published on: May 9, 2025

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
Cancer-Critical Genes II: Tumor Suppressor Genes01:05

Cancer-Critical Genes II: Tumor Suppressor Genes

Genes usually encode proteins necessary for the proper functioning of a healthy cell. Mutations can often cause changes to the gene expression pattern, thereby altering the phenotype.
When the function of certain critical genes, especially those involved in cell cycle regulation and cell growth signaling cascades, gets disrupted, it upsets the cell cycle progression. Such cells with unchecked cell cycles start proliferating uncontrollably and eventually develop into tumors.
Such genes that act...
Cancer-Critical Genes II: Tumor Suppressor Genes01:05

Cancer-Critical Genes II: Tumor Suppressor Genes

Genes usually encode proteins necessary for the proper functioning of a healthy cell. Mutations can often cause changes to the gene expression pattern, thereby altering the phenotype.
When the function of certain critical genes, especially those involved in cell cycle regulation and cell growth signaling cascades, gets disrupted, it upsets the cell cycle progression. Such cells with unchecked cell cycles start proliferating uncontrollably and eventually develop into tumors.
Such genes that act...
Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.